December 23, 2024 04:48 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Cylinder blast at a temple in Karnataka's Hubbali injures nine people | Kuwait PM personally sees off Modi at airport as Indian premier concludes two-day trip | Three pro-Khalistani terrorists, who attacked a police outpost in Gurdaspur, killed in an encounter | Who is Sriram Krishnan, an Indian-American picked by Donald Trump as US AI policy advisor? | Mohali building collapse: Death toll rises to 2, many feared trapped for 17 hours | 4-year-old killed after speeding car driven by a teen hits him in Mumbai | PM Modi attends opening ceremony of Arabian Gulf Cup in Kuwait | Jaipur gas tanker crash: Toll touches 14, 30 critical | Arrest warrant against former cricketer Robin Uthappa over 'PF fraud' | PM Modi emplanes for a visit to Kuwait
COVID-19: GSK-Vir drug 'works' against all Omicron mutations

COVID-19: GSK-Vir drug 'works' against all Omicron mutations

Dec 07, 2021, at 11:06 pm

New York: GlaxoSmithKline plc and Vir Biotechnology, Inc. on Tuesday announced an update to preclinical data on bioRxiv, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant (B.1.1.529).